Novel Thyrointegrin {alpha}v{beta}3 Antagonist for the Treatment of Acute Myeloid Leukemia

In conclusion, P-bi-TAT is a promising lead clinical candidate that warrants clinical trials in AML patients.DisclosuresMousa: NanoPharmaceuticals LLC: Equity Ownership, Patents & Royalties. Davis: NanoPharmaceuticals LLC: Employment, Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Mousa, S. A., Sudha, T. I., Godugu, K., Rajabi, M., Tipu, N., Davis, P. J. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Source Type: research